Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PRTA 
Prothena Corporation plc (PRTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: PRTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.33
1 Year Target Price $20.33
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.6% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 495.77M USD | Price to earnings Ratio - | 1Y Target Price 20.33 |
Price to earnings Ratio - | 1Y Target Price 20.33 | ||
Volume (30-day avg) 10 | Beta -0.1 | 52 Weeks Range 4.32 - 16.66 | Updated Date 12/19/2025 |
52 Weeks Range 4.32 - 16.66 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1646.42% |
Management Effectiveness
Return on Assets (TTM) -29.31% | Return on Equity (TTM) -67.63% |
Valuation
Trailing PE - | Forward PE 11.59 | Enterprise Value 183702530 | Price to Sales(TTM) 42.06 |
Enterprise Value 183702530 | Price to Sales(TTM) 42.06 | ||
Enterprise Value to Revenue 15.59 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53829982 | Shares Floating 43391810 |
Shares Outstanding 53829982 | Shares Floating 43391810 | ||
Percent Insiders 19.2 | Percent Institutions 79.83 |
Upturn AI SWOT
Prothena Corporation plc
Company Overview
History and Background
Prothena Corporation plc is a biopharmaceutical company founded in 2012 as a spin-off from Elan Corporation plc. Its primary focus is on developing innovative therapies for neurodegenerative diseases and other debilitating conditions. Key milestones include the progression of its pipeline candidates through clinical trials and strategic partnerships.
Core Business Areas
- Neurodegenerative Diseases: Prothena is dedicated to discovering, developing, and commercializing therapies for patients suffering from devastating neurodegenerative diseases, particularly those involving protein aggregation. This includes Alzheimer's disease, Parkinson's disease, and other related conditions.
- Rare Inflammatory Diseases: The company is also developing novel therapies for rare inflammatory conditions, aiming to address unmet medical needs in these patient populations.
Leadership and Structure
Prothena Corporation plc is led by a seasoned management team with expertise in drug development and commercialization. The company operates under a typical corporate structure with departments for research and development, clinical operations, regulatory affairs, manufacturing, and commercialization. Specific leadership details are available on the company's investor relations website.
Top Products and Market Share
Key Offerings
- PRX005: A novel antibody targeting tau pathology for the treatment of Alzheimer's disease. Currently in Phase 1 clinical trials. Competitors in the Alzheimer's disease space include numerous large pharmaceutical companies and smaller biotech firms developing various approaches, including amyloid-beta targeting therapies and tau-targeting agents.
- PRX004: A novel antibody targeting transthyretin (ATTR) amyloidosis for the treatment of both hereditary and wild-type ATTR amyloidosis. This product has demonstrated promising results in clinical trials and is advancing towards potential regulatory submission. Competitors in the ATTR amyloidosis market include companies with approved therapies like Pfizer (Vyndaqel) and Ionis Pharmaceuticals (Tegsedi).
- PRX012: A novel antibody targeting amyloid beta for the treatment of Alzheimer's disease. Currently in Phase 1 clinical trials. Competitors in the amyloid beta targeting space for Alzheimer's include companies like Eli Lilly (Donanemab) and Biogen/Eisai (Leqembi).
Market Dynamics
Industry Overview
Prothena operates within the biopharmaceutical industry, specifically focusing on novel therapies for neurological and rare diseases. This sector is characterized by high R&D costs, long development timelines, stringent regulatory requirements, and significant unmet medical needs. The market is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in scientific understanding of disease mechanisms.
Positioning
Prothena is positioned as an innovative biopharmaceutical company with a strong focus on addressing challenging proteinopathies and inflammatory diseases. Its competitive advantage lies in its proprietary technology platform, deep scientific expertise in protein misfolding and aggregation, and a pipeline of novel therapeutic candidates targeting validated and emerging disease pathways. The company aims to be a leader in developing transformative treatments for diseases with limited or no effective therapies.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's disease and ATTR amyloidosis is substantial and growing, estimated to be in the tens of billions of dollars annually. Prothena is positioned to capture a significant portion of this market as its lead candidates advance through development and gain regulatory approval. The TAM for rare inflammatory diseases also represents a considerable opportunity depending on the specific conditions targeted.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for targeting proteinopathies.
- Experienced management team with strong scientific and clinical development expertise.
- Pipeline of promising drug candidates in various stages of clinical development.
- Focus on significant unmet medical needs in neurodegenerative and rare inflammatory diseases.
- Strategic collaborations and partnerships.
Weaknesses
- Reliance on clinical trial success, which carries inherent risks.
- Long development timelines and significant R&D expenditures.
- Limited product revenue currently, as most candidates are in development.
- Need for substantial future funding to bring products to market.
Opportunities
- Growing global demand for treatments for neurodegenerative diseases.
- Advancements in understanding disease mechanisms enabling new therapeutic approaches.
- Potential for orphan drug designations and expedited regulatory pathways for rare diseases.
- Expansion into new therapeutic areas based on the core technology platform.
- Acquisition or licensing opportunities for promising early-stage assets.
Threats
- Failure of drug candidates in clinical trials.
- Intense competition from established pharmaceutical companies and other biotechs.
- Changes in regulatory requirements and reimbursement policies.
- Patent challenges and intellectual property disputes.
- Economic downturns impacting healthcare spending and investment.
Competitors and Market Share
Key Competitors
- Eli Lilly and Company (LLY)
- Biogen Inc. (BIIB)
- Pfizer Inc. (PFE)
- Ionis Pharmaceuticals, Inc. (IONS)
- AbbVie Inc. (ABBV)
Competitive Landscape
Prothena faces a competitive landscape with large, established pharmaceutical companies that have significant resources for R&D, manufacturing, and commercialization. Prothena's advantage lies in its specialized focus on novel mechanisms of action for difficult-to-treat diseases and its agility as a smaller, focused biotech. However, it must contend with the deep pipelines, established market access, and extensive clinical trial experience of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Prothena's historical growth has been characterized by the advancement of its pipeline, building a strong scientific foundation, and securing strategic partnerships. The company has consistently focused on expanding its research and development capabilities and progressing its lead drug candidates through clinical trials.
Future Projections: Future growth projections for Prothena are contingent on the successful progression of its pipeline candidates through clinical development and subsequent regulatory approvals. Analyst estimates will focus on potential peak sales for approved drugs and the overall market opportunity. The company anticipates significant growth upon successful commercialization of its therapies.
Recent Initiatives: Recent initiatives likely include the initiation or expansion of clinical trials for its key pipeline assets, forging new strategic partnerships, and potentially preparing for regulatory submissions. Continued investment in R&D and talent acquisition are also key ongoing initiatives.
Summary
Prothena Corporation plc is a promising biopharmaceutical company focused on developing innovative treatments for neurodegenerative and rare inflammatory diseases. Its strengths lie in its specialized technology and pipeline of novel drug candidates, particularly in the Alzheimer's and ATTR amyloidosis space. However, the company faces significant risks associated with drug development and intense competition from larger players. Continued success hinges on positive clinical trial outcomes and effective execution of its development and commercialization strategies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC EDGAR)
- Pharmaceutical Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is generated for informational purposes only and does not constitute financial or investment advice. The data presented is based on publicly available information and may not be exhaustive or entirely up-to-date. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.prothena.com |
Full time employees 163 | Website https://www.prothena.com | ||
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.